Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. The MDS Clinical Research Consortium

    ... The MDS Clinical Research Consortium (MDS- CRC) is an unprecedented, six-institution group ...

    Article last updated 10/17/2018 - 9:36am.

  2. Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

    ... This study led by Dr. Eric Padron through the MDS Clinical Research Consortium sites showed promising results for a new CMML ...

    Article last updated 10/17/2018 - 10:10am.

  3. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis

    ... with ring sideroblasts (RS) and relatively favorable clinical outcomes. The 2016 World Health Organization classification ... known SF3B1 mutational status were identified from MDS Clinical Research Consortium institutions and grouped when possible as 5% to 15% ...

    Research Article last updated 07/18/2018 - 8:07am.

  4. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

    ... patients with an IDH2 mutation. This discovery led to a clinical trial involving AG-221 for the treatment of MDS with an IDH2 ... were able to secure the assistance of the MDS Clinical Research Consortium and expand the trial to the CRC’s six participating ...

    Article last updated 08/30/2018 - 1:32pm.

  5. Dr. Komrokji on the Changing Landscape of AML

    ... Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses ...

    Article last updated 09/10/2018 - 11:55am.

  6. CHIP – A Promising Genetic Discovery for MDS, AML and Cardiovascular Disease

    ... affect cardiovascular disease.  An example of this is new research that has shown how a buildup of mutated stem cells in the bone ... Clonal hematopoiesis cannot be treated directly, but clinical management includes monitoring for disease progression and attention ...

    Article last updated 08/30/2018 - 3:14pm.

  7. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network.

    ... To address this issue, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) convened a group of international experts in ... and propose initiatives to facilitate clinical and biologic research. Key conclusions of the working group were: (1) new patients should ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

    ... receiving azanucleoside therapy is unknown. In the MDS Clinical Research Consortium database, we compared the prognostic utility of the ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Optimizing management of myelodysplastic syndromes post-allogeneic transplantation

    ... preemptive therapy is an important goal of current clinical research . Further strategies aiming at an improved prevention of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes

    ... to prevent relapse, is an important goal of current clinical research . There is an urgent need for prospective randomized trials to ...

    Research Article last updated 07/20/2018 - 5:14pm.